(250 days)
No
The description focuses on data routing and formatting, with no mention of AI/ML terms or capabilities like learning, prediction, or complex data analysis beyond simple forwarding.
No
The device provides supplemental information about patient alarms and medical-related events to healthcare professionals; it does not directly treat or diagnose a disease or condition, which is a characteristic of a therapeutic device.
No
The "Intended Use / Indications for Use" section explicitly states, "This product is not intended to provide real-time information, nor is it a source of patient alarms, nor is it a replacement for alarming devices." It processes information from other devices, rather than performing a diagnostic function itself.
Yes
The device description explicitly states "iSirona Magellan, is an on-site messaging integration solution" and describes its function as forwarding information obtained from other medical devices. It utilizes existing hospital network infrastructure and third-party devices for display, indicating it is a software solution that integrates with existing hardware, rather than a hardware device itself. The performance studies focus on software testing and performance testing of the software's functionality.
Based on the provided information, the iSirona Magellan software solution is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the software provides "supplemental information about patient alarms and other medical-related events." It explicitly says it is "not intended to provide real-time information, nor is it a source of patient alarms, nor is it a replacement for alarming devices." This indicates it's a communication and notification tool, not a diagnostic tool that analyzes biological samples or provides diagnostic information.
- Device Description: The description reinforces that it's an "on-site messaging integration solution which forwards information about patient alarms and other medical-related events obtained from information sources such as patient monitors, ventilators, infusion pumps, etc." It acts as a relay for existing information, not a generator or analyzer of diagnostic data.
- Lack of IVD Characteristics: The document does not mention any of the typical characteristics of an IVD, such as:
- Analysis of biological samples (blood, urine, tissue, etc.)
- Providing diagnostic or prognostic information based on sample analysis
- Use of reagents or other IVD-specific components
The iSirona Magellan software is designed to improve communication and workflow related to existing medical device alarms and events. It does not perform any in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The iSirona Magellan software solution provides healthcare professionals with supplemental information about patient alarms and other medical-related events. The product can route all or subsets of this information to selective remote devices such as centralized computer stations and mobile communication devices. Receipt of alarm messages or events by the centralized computer stations and/or mobile communication devices is not confirmed and delivery to the end device is not guaranteed. The primary alarm notification is the device producing the alarm or event. This product is not intended to provide real-time information, nor is it a source of patient alarms, nor is it a replacement for alarming devices.
Product codes
MSX
Device Description
iSirona Magellan, is an on-site messaging integration solution which forwards information about patient alarms and other medical-related events obtained from information sources such as patient monitors, ventilators, infusion pumps, etc. to the user. The user receives the information via selective remote devices such as centralized computer stations and mobile communication devices provided by third-party companies. iSirona Magellan utilizes the existing hospital network to process data and relay secondary notifications. It is not to be considered a primary alarming device.
iSirona Magellan connects to the information sources through wired ethernet connections which are part of the customer's infrastructure. The user configures iSirona Magellan to determine which information, including alarm notifications, is delivered to which users, iSirona Magellan then formats the data for wireless delivery to the centralized computer stations and mobile communication devices.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Software Testing: Software was designed and developed according to a robust software development process, and was rigorously verified and validated. Software information is provided in accordance with internal requirements and the following standards and guidance documents: FDA guidance: The content of premarket submissions for software contained in medical devices, 11 May 05; FDA guidance: Off-the-shelf software use in medical devices, 09 Sep 99; FDA guidance: General principles of software validation; Final guidance for industry and FDA staff, 11 Jan 02; and FDA guidance: Cybersecurity for networked medical devices containing off-the-shelf (OTS) software, 14 January 2005. Test results indicate that iSirona Magellan complies with its predetermined specifications, and applicable standards and guidance documents.
Performance Testing: iSirona Magellan was tested for performance in accordance with internal requirements. Test results indicate that iSirona Magellan complies with its predetermined specifications and the applicable standards.
Conclusion: Verification and validation activities were conducted to establish the performance and safety characteristics of iSirona Magellan. The results of these activities demonstrate that iSirona Magellan is safe and effective when used in accordance with its intended use and labeling. Therefore, iSirona Magellan is considered substantially equivalent to the predicate device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).
0
510(k) Summary
| Submission Date: | 30 September 2013 | ||
|---|---|---|---|
| Submitter: | iSirona, LLC | ||
| 430 West 5th Street, Suite 800 | |||
| Panama City, FL 32401 USA | |||
| Submitter Contact: | Mr. Rabi Nur | ||
| Phone: +1 (850) 250-3966 | |||
| Email: Rabi.Nur@isirona.com | NOV 2 0 2013 | ||
| Application | |||
| Correspondent: | Mr. Thomas Kroenke | ||
| Principal Consultant | |||
| Speed To Market, Inc. | |||
| PO Box 3018 | |||
| Nederland, CO 80466 USA | |||
| tkroenke@speedtomarket.net | |||
| 303 956 4232 | |||
| Manufacturing Site: | iSirona, LLC | ||
| 430 West 5th Street, Suite 800 | |||
| Panama City, FL 32401 USA | |||
| Trade Name: | iSirona Magellan | ||
| Common Name: | System, Network And Communication, Physiological Monitors | ||
| Classification Name: | System, Network And Communication, Physiological Monitors | ||
| Classification | |||
| Regulation: | 21 CFR §870.2300 | ||
| Product Code: | MSX | ||
| Substantially | |||
| Equivalent Devices: | New iSirona Model | Predicate | |
| 510(k) Number | Predicate | ||
| Manufacturer / Model | |||
| iSirona Magellan | K102974 | Philips Medical Systems / | |
| Philips Emergin Event | |||
| Management System |
·
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
1
510(k) Summary
Device Description:
iSirona Magellan, is an on-site messaging integration solution which forwards information about patient alarms and other medical-related events obtained from information sources such as patient monitors, ventilators, infusion pumps, etc. to the user. The user receives the information via selective remote devices such as centralized computer stations and mobile communication devices provided by third-party companies. iSirona Magellan utilizes the existing hospital network to process data and relay secondary notifications. It is not to be considered a primary alarming device.
iSirona Magellan connects to the information sources through wired ethernet connections which are part of the customer's infrastructure. The user configures iSirona Magellan to determine which information, including alarm notifications, is delivered to which users, iSirona Magellan then formats the data for wireless delivery to the centralized computer stations and mobile communication devices.
Intended Use: The iSirona Magellan software solution provides healthcare professionals with supplemental information about patient alarms and other medical-related events. The product can route all or subsets of this information to selective remote devices such as centralized computer stations and mobile communication devices. Receipt of alarm messages or events by the centralized computer stations and/or mobile communication devices is not confirmed and delivery to the end device is not guaranteed. The primary alarm notification is the device producing the alarm or event. This product is not intended to provide real-time information, nor is it a source of patient alarms, nor is it a replacement for alarming devices.
Technology Comparison:
iSirona Magellan employs the same technological characteristics as the predicate device.
| Characteristic | Predicate Device | Proposed Device |
|---|---|---|
| Serves as secondary means of | ||
| unnunciating patient events | Yes | Same |
| Relays information from primary | ||
| medical device to display device | Yes | Same |
| Transmission of any aların from a | ||
| medical device | Yes | Same |
| Waveform data | Yes, static waveform | |
| data. | Same | |
| Supported medical device inputs | Various manufacturers | I II.7 compatible devices |
| Fixed display devices | Unknown | Yes, agnostic gateway |
| Mobile display devices | Pagers | Android devices running |
| version 4.0.3 or greater |
Page 2 of 3
2
510(k) Summary
.
.
ﺮ
Summary of Performance Testing:
| Software Testing | Software was designed and developed according to a robust software development process, and was rigorously verified and validated.
Software information is provided in accordance with internal requirements and the following standards and guidance documents:
FDA guidance: The content of premarket submissions for software contained in medical devices, 11 May 05; FDA guidance: Off-the-shelf software use in medical devices, 09 Sep 99; FDA guidance: General principles of software validation; Final guidance for industry and FDA staff, 11 Jan 02; and FDA guidance: Cybersecurity for networked medical devices containing off-the-shelf (OTS) software, 14 January 2005. Test results indicate that iSirona Magellan complies with its predetermined specifications, and applicable standards and guidance documents. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Performance Testing | iSirona Magellan was tested for performance in accordance with internal requirements.
Test results indicate that iSirona Magellan complies with its predetermined specifications and the applicable standards. |
| Conclusion | Verification and validation activities were conducted to establish the performance and safety characteristics of iSirona Magellan. The results of these activities demonstrate that iSirona Magellan is safe and effective when used in accordance with its intended use and labeling.
Therefore, iSirona Magellan is considered substantially equivalent to the predicate device. |
.
.
:
ﺎ
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
November 20, 2013
iSirona, LLC c/o Thomas Kroenke Principal Consultant Speed to Market, Inc. PO Box 3018 Nederland, CO 80466
K130707 Re:
Trade/Device Name: iSirona magellan Regulation Number: 21 CFR 870.2300 Regulation Name: System, Network and Communication, Physiological Monitors Regulatory Class: Class II (two) Product Code: MSX Dated: October 10, 2013 Received: October 11, 2013
Dear Thomas Kroenke:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Thomas Kroenke
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, Misbranding by reference to premarket notification (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htmfor the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Owen P. Faris -S
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
K130707 Page 1 of 1
Indications for Use
K
iSirona Magellan
5 10(k) Number (if known):
Device Name:
Indications for Use:
The iSirona Magellan software solution provides healthcare professionals with supplemental information about patient alarms and other medical-related events. The product can route all or subsets of this information to selective remote devices such as centralized computer stations and mobile communication devices. Receipt of alarm messages or events by the centralized computer stations and/or mobile communication devices is not confirmed and delivery to the end device is not guaranteed. The primary alarm notification is the device producing the alarm or event. This product is not intended to provide real-time information, nor is it a source of patient alarms, nor is it a replacement for alarming devices.
X Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Digitally signed by Owen P. Farls
Date: 2011.11.20 10:29:54 -05'00'
Page 1 of 1